瘤内微环境和基于昆虫的药物设计:在瘤学和免疫瘤学中可预见的未来
Karolina Kaźmierczak-Siedlecka1,2, Robert Kucharski1,2, Ewa Stachowska3
1Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, Gdansk, Poland.
Frontiers in pharmacology
|February 16, 2026
概括
瘤微环境 (TME) 包括微生物和细胞. 了解内微生物组是开发新癌症治疗方法和改善瘤学药物发现的关键.
科学领域:
- 在瘤学瘤学.
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 瘤微环境 (TME) 包括微生物,免疫细胞,纤维细胞和内皮细胞.
- 人们越来越认识到内微生物组在癌症免疫力和耐药性方面的作用.
- 整合瘤免疫和微生物组为精确瘤学提供了一个有希望的途径.
研究的目的:
- 突出描述内微生物特征对于药物发现的重要性.
- 探索涉及TME微生物组的治疗策略,包括微生物消除,免疫轴调节和工程细菌.
- 强调先进模型的实用性,如瘤有机体-免疫共同培养和3D生物打印用于研究微生物群-免疫相互作用.
主要方法:
- 对TME微生物组表征和治疗调制的当前方法的审查.
- 讨论用于局部瘤治疗的工程细菌菌株.
- 利用瘤有机体-免疫共同培养和3D生物打印模型.
主要成果:
- 内微生物特征极大地影响治疗疗效和耐药性.
- 微生物组调节策略可以影响瘤进展和治疗结果.
- 先进的共同培养和生物打印模型促进了瘤-微生物组-免疫交叉的剖析.
结论:
- 免疫系统和与瘤相关的微生物组之间的相互作用在瘤学中提供了新的治疗机会.
- 准TME微生物组是增强抗癌疗法的有希望的策略.
- 对微生物组-免疫轴的进一步研究可以推动免疫瘤学的创新.
相关概念视频
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K


